Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
CanadaIPO:
03 September 2014Website:
http://www.auriniapharma.comNext earnings report:
14 February 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Tue, 19 Nov 2024 23:14:25 GMTDividend
Analysts recommendations
Institutional Ownership
AUPH Latest News
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), announced today the acceptance of four poster presentations at the annual American College of Rheumatology Convergence (ACR) 2024 taking place in Washington, D.C., November 14-19. The data highlight the need for additional screening for lupus nephritis (LN), a serious manifestation of systemic lupus erythematosus (SLE), and reinforce the clinical importance of LUPKYNIS® (vo.
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia to Participate in Jefferies London Healthcare Conference.
Today, we are following up on biopharma name Aurinia Pharmaceuticals Inc. The company just posted solid Q3 results this week and announced significant cost reduction measures. Aurinia is seeing impressive sales growth, has a pristine balance sheet and should become increasingly profitable in coming years.
Aurinia Pharmaceuticals (AUPH) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to loss of $0.09 per share a year ago.
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Presents New Data Highlighting Real-World Utilization and Value of LUPKYNIS® in Treating Lupus Nephritis at ASN Kidney Week 2024.
Aurinia Pharmaceuticals' LUPKYNIS, an FDA-approved treatment for lupus nephritis, is well-positioned to become a new standard of care due to its dual role in immunosuppression and kidney protection. The partnership with Otsuka Pharmaceutical supports Aurinia's international expansion into European and Asian markets. AUR200, now in Phase 1 trials, could be a significant future value driver targeting autoimmune diseases.
Aurinia Pharmaceuticals shows promising growth with increased Lupkynis sales. The near future could see a $10M milestone for Japanese approval and royalty payments from Japanese sales. AUPH is developing AUR200, with a phase 1 trial underway allowing it to diversify beyond Lupkynis. The Company reported a $722K net income for Q2'24, up from a $10.7M net loss in Q1'24.
Aurinia Pharmaceuticals, Inc. (NASDAQ:AUPH ) Q2 2024 Earnings Conference Call August 1, 2024 8:30 AM ET Company Participants Andrea Christopher - Head, Corporate Communications & IR Peter Greenleaf - President, CEO & Director Greg Keenan - Chief Medical Officer Joe Miller - CFO Conference Call Participants Joseph Schwartz - Leerink Partners Stacy Ku - TD Cowen Ed Arce - H.C. Wainwright & Co. Operator Good day, ladies and gentlemen.
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 1, 2024.
Aurinia (AUPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
What type of business is Aurinia Pharmaceuticals?
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
What sector is Aurinia Pharmaceuticals in?
Aurinia Pharmaceuticals is in the Healthcare sector
What industry is Aurinia Pharmaceuticals in?
Aurinia Pharmaceuticals is in the Biotechnology industry
What country is Aurinia Pharmaceuticals from?
Aurinia Pharmaceuticals is headquartered in Canada
When did Aurinia Pharmaceuticals go public?
Aurinia Pharmaceuticals initial public offering (IPO) was on 03 September 2014
What is Aurinia Pharmaceuticals website?
https://www.auriniapharma.com
Is Aurinia Pharmaceuticals in the S&P 500?
No, Aurinia Pharmaceuticals is not included in the S&P 500 index
Is Aurinia Pharmaceuticals in the NASDAQ 100?
No, Aurinia Pharmaceuticals is not included in the NASDAQ 100 index
Is Aurinia Pharmaceuticals in the Dow Jones?
No, Aurinia Pharmaceuticals is not included in the Dow Jones index
When was Aurinia Pharmaceuticals the previous earnings report?
No data
When does Aurinia Pharmaceuticals earnings report?
The next expected earnings date for Aurinia Pharmaceuticals is 14 February 2025